- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Updated Software for Faster Low-Field MRI Brain Scans
The ninth FDA clearance for the Swoop Portable MR Imaging system is for new software that enables significant scan time reduction for brain MRI scans.
The Swoop Portable MR Imaging system has garnered another FDA 510(k) clearance for new software that may facilitate more expedient diagnosis of neurological conditions.
The updated software reportedly offers significant reduction of scan times, facilitating use of the device’s ultra-low-field magnetic resonance imaging (MRI) capabilities in acute care settings, according to Hyperfine, the manufacturer of the Swoop Portable MR Imaging system.
A newly FDA-cleared software update for the Swoop Portable MR Imaging system facilitates significantly reduced scan times for low-field MRI brain imaging, according to Hyperfine, the manufacturer of the MRI system. (Image courtesy of Hyperfine.)
“Timely MR brain imaging is essential for clinicians making critical treatment decisions, particularly in acute neurological episodes like strokes. We have been an active site in the ACTION PMR study assessing the use of the Swoop® system in stroke diagnosis, and this latest software will help the Swoop® system more seamlessly integrate into stroke workflows,” noted Adnan Siddiqui, M.D., Ph.D., a professor and vice-chairman in the Department of Neurosurgery at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences.
Hyperfine added that the reduced acquisition time for MRI sequences with the new software may help mitigate the impact of patient motion on brain scan quality.
Diffusion-Weighted MRI and Neoadjuvant Chemotherapy for Rectal Cancer: What New Research Reveals
September 3rd 2024In a comparison of imaging assessments to gauge the effectiveness of neoadjuvant chemotherapy for rectal adenocarcinoma, researchers found the combination of diffusion-weighted imaging and MR tumor regression grading had a 90 percent area under the curve (AUC) and a negative predictive value (NPV) of 93 percent.
New Research Highlights Emerging MRI Contrast Agent for Bladder Imaging
August 21st 2024A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
MRI Study Offers Insights on Traumatic Brain Injury and Cerebral Microbleeds
August 19th 2024Detecting cerebral microbleed (CMB) in one of six healthy adults in a new study, researchers also found that CMB was the only MRI marker of small vessel disease (SVD) to be significantly associated with traumatic brain injury (TBI).
